Udifitimod  (Synonyms: BMS-986166)

Udifitimod (BMS-986166) is a potent, selective and orally active S1P1R modulator. Udifitimod has the potential for the research of autoimmune diseases^[1][2].

Udifitimod (0.1, 0.5 mg/kg; p.o.; once daily for 21 days) shows anti-inflammation activity in autoimmune encephalomyelitis model ^[1].
Udifitimod (0.1, 0.5 mg/kg; p.o.; once daily for 50 days) reduces the clinical score as well as the paw histology score in the collagen-induced arthritis (CIA) model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

379.54

C₂₅H₃₃NO₂

1883345-06-9

OC[C@]1(N)C[C@@H](C2=CC=C3C[C@H](CCC4=CC=CC=C4OC)CCC3=C2)CC1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Bihorel S, et al. Population Pharmacokinetic Analysis of BMS-986166, a Novel Selective Sphingosine-1-Phosphate-1 Receptor Modulator, and Exposure-Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan;10(1):8-21.  [Content Brief]

  [2]. Gilmore JL, et al. Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P1) Modulator Advanced into Clinical Trials. J Med Chem. 2019 Mar 14;62(5):2265-2285.  [Content Brief]